• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

最贫困的十亿人中的克罗恩病:中低收入国家的克罗恩病负担。

Crohn's Disease Among the Poorest Billion: Burden of Crohn's Disease in Low- and Lower-Middle-Income Countries.

机构信息

Division of Global Health Equity, Department of Medicine, Brigham and Women's Hospital, Boston, MA, 02115, USA.

Department of Global Health and Social Medicine, Harvard Medical School, Boston, MA, 02199, USA.

出版信息

Dig Dis Sci. 2023 Apr;68(4):1226-1236. doi: 10.1007/s10620-022-07675-6. Epub 2022 Aug 31.

DOI:10.1007/s10620-022-07675-6
PMID:36044105
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10102033/
Abstract

BACKGROUND

To establish the epidemiology and patterns of care of Crohn's Disease in low- and lower-middle-income countries.

METHODS

A cross-sectional survey of gastroenterology providers in countries where the world's poorest billion live was conducted to learn more about the state of diagnostic and treatment capacity for Crohn's. Quantitative data were analyzed in R and Excel.

RESULTS

A total of 46 survey responses from 15 countries were received, giving a response rate of 54.8%. All responses collected were from providers practicing in Africa and South Asia. The mean number of patients with Crohn's cared for in the last year was 89.5 overall but ranged from 0 reported at one facility in Rwanda to 1000 reported at two different facilities in India. Overall, Crohn's disease made up 20.6% of the inflammatory bowel disease diagnoses reported by survey respondents, with Africa exhibiting a larger proportion of Crohn's compared to ulcerative colitis than Asia. Most providers reported that patients with Crohn's have symptoms for 6-24 months prior to diagnosis and that 26-50% of their patients live in rural areas. The most reported diagnostic challenges are differentiating between Crohn's and intestinal tuberculosis, poor disease awareness, and lack of trained pathologists. The most widely reported challenge in managing Crohn's disease is patients' inability to afford biologics, reported by 65% of providers.

CONCLUSION

Our study suggests there may be a greater burden of Crohn's disease in low- and lower-middle-income countries than is indicated in prior literature. Respondents reported many challenges in diagnosing and treating Crohn's disease.

摘要

背景

了解低收入和中低收入国家克罗恩病的流行病学和治疗模式。

方法

对世界上最贫困的 10 亿人所在国家的胃肠病学医生进行了横断面调查,以了解克罗恩病的诊断和治疗能力状况。在 R 和 Excel 中对定量数据进行了分析。

结果

共收到来自 15 个国家的 46 份调查回复,回复率为 54.8%。所有回复均来自非洲和南亚的执业医生。过去一年中,每位医生平均诊治的克罗恩病患者为 89.5 例,但范围从卢旺达一家机构报告的 0 例到印度两家机构报告的 1000 例。总体而言,克罗恩病占调查对象报告的炎症性肠病诊断的 20.6%,非洲的克罗恩病比例高于溃疡性结肠炎,而亚洲则相反。大多数医生报告称,克罗恩病患者在确诊前有 6-24 个月的症状,且 26-50%的患者居住在农村地区。最常报告的诊断挑战是区分克罗恩病和肠结核、疾病认知度低以及缺乏训练有素的病理学家。最常报告的克罗恩病管理挑战是患者无法负担生物制剂,65%的医生报告了这一挑战。

结论

我们的研究表明,低收入和中低收入国家的克罗恩病负担可能比之前文献所表明的更重。调查对象报告了在诊断和治疗克罗恩病方面存在诸多挑战。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6cd/10102033/e70d928ab1ff/10620_2022_7675_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6cd/10102033/1d6d5a27f2d1/10620_2022_7675_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6cd/10102033/4c381143aa58/10620_2022_7675_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6cd/10102033/f62f7fd49b20/10620_2022_7675_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6cd/10102033/d5650d897d67/10620_2022_7675_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6cd/10102033/e70d928ab1ff/10620_2022_7675_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6cd/10102033/1d6d5a27f2d1/10620_2022_7675_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6cd/10102033/4c381143aa58/10620_2022_7675_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6cd/10102033/f62f7fd49b20/10620_2022_7675_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6cd/10102033/d5650d897d67/10620_2022_7675_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6cd/10102033/e70d928ab1ff/10620_2022_7675_Fig5_HTML.jpg

相似文献

1
Crohn's Disease Among the Poorest Billion: Burden of Crohn's Disease in Low- and Lower-Middle-Income Countries.最贫困的十亿人中的克罗恩病:中低收入国家的克罗恩病负担。
Dig Dis Sci. 2023 Apr;68(4):1226-1236. doi: 10.1007/s10620-022-07675-6. Epub 2022 Aug 31.
2
Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies.21 世纪全球炎症性肠病的发病率和流行率:基于人群的系统综述研究。
Lancet. 2017 Dec 23;390(10114):2769-2778. doi: 10.1016/S0140-6736(17)32448-0. Epub 2017 Oct 16.
3
Prevalence of inflammatory bowel disease in the Australian general practice population: A cross-sectional study.澳大利亚普通人群中炎症性肠病的流行情况:一项横断面研究。
PLoS One. 2021 May 27;16(5):e0252458. doi: 10.1371/journal.pone.0252458. eCollection 2021.
4
A national survey on the patterns of treatment of inflammatory bowel disease in Canada.一项关于加拿大炎症性肠病治疗模式的全国性调查。
BMC Gastroenterol. 2003 Jun 5;3:10. doi: 10.1186/1471-230X-3-10.
5
Crohn's disease in low and lower-middle income countries: A scoping review.低收入和中低收入国家的克罗恩病:一项范围综述
World J Gastroenterol. 2020 Nov 21;26(43):6891-6908. doi: 10.3748/wjg.v26.i43.6891.
6
Proportion of inflammatory bowel diseases patients with suboptimal disease control in daily clinical practice-Real-world evidence from the inflammatory bowel diseases-podcast study.在日常临床实践中炎症性肠病患者疾病控制不佳的比例——来自炎症性肠病播客研究的真实世界证据。
United European Gastroenterol J. 2024 Jul;12(6):705-716. doi: 10.1002/ueg2.12572. Epub 2024 May 11.
7
Familial occurrence and inheritance studies in inflammatory bowel disease.炎症性肠病的家族发病情况及遗传研究。
Neth J Med. 1996 Feb;48(2):53-6. doi: 10.1016/0300-2977(95)00093-3.
8
[Incidence of inflammatory bowel diseases in Bretagne (1994-1995). ABERMAD. Association Bertonne d'Etude et de Recherche des Maladies de l'Appareil Digesif].布列塔尼地区炎症性肠病的发病率(1994 - 1995年)。ABERMAD。贝托讷消化器官疾病研究与协会
Gastroenterol Clin Biol. 1997;21(6-7):483-90.
9
Paediatric inflammatory bowel disease in New Zealand.新西兰的儿童炎症性肠病
N Z Med J. 2008 Oct 3;121(1283):19-34.
10
[Trends in the occurrence (1980-1999) and clinical features of Crohn's disease and ulcerative colitis in a university hospital in southeastern Brazil].[巴西东南部一所大学医院克罗恩病和溃疡性结肠炎的发病趋势(1980 - 1999年)及临床特征]
Arq Gastroenterol. 2002 Apr-Jun;39(2):98-105. doi: 10.1590/s0004-28032002000200006. Epub 2003 Feb 19.

引用本文的文献

1
Global Training in Inflammatory Bowel Disease: Addressing Growing Challenges in IBD.炎症性肠病的全球培训:应对炎症性肠病日益增长的挑战
Dig Dis Sci. 2025 Jul 24. doi: 10.1007/s10620-025-09263-w.
2
Global, regional and national burden of inflammatory bowel disease in females from 1990 to 2021: an analysis of the global burden of disease study 2021.1990年至2021年全球女性炎症性肠病的全球、区域和国家负担:全球疾病负担研究2021分析
Front Glob Womens Health. 2025 May 29;6:1580451. doi: 10.3389/fgwh.2025.1580451. eCollection 2025.
3
Developing IBD counsellors in low- and middle-income countries: bridging gaps in patient care.

本文引用的文献

1
The Role of Diet in the Pathogenesis and Management of Inflammatory Bowel Disease: A Review.饮食在炎症性肠病发病机制和治疗中的作用:综述。
Nutrients. 2020 Dec 31;13(1):135. doi: 10.3390/nu13010135.
2
Crohn's disease in low and lower-middle income countries: A scoping review.低收入和中低收入国家的克罗恩病:一项范围综述
World J Gastroenterol. 2020 Nov 21;26(43):6891-6908. doi: 10.3748/wjg.v26.i43.6891.
3
The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.
在低收入和中等收入国家培养炎症性肠病顾问:弥合患者护理差距
EClinicalMedicine. 2025 Apr 24;83:103218. doi: 10.1016/j.eclinm.2025.103218. eCollection 2025 May.
4
Living Engineered Bacterial Therapeutics: Emerging Affordable Precision Interventions.活体工程菌治疗学:新兴的平价精准干预手段
Microb Biotechnol. 2024 Nov;17(11):e70057. doi: 10.1111/1751-7915.70057.
5
Diagnostic strategy of irritable bowel syndrome: a low- and middle-income country perspective.肠易激综合征的诊断策略:低收入和中等收入国家视角
Intest Res. 2024 Jul;22(3):286-296. doi: 10.5217/ir.2023.00199. Epub 2024 Mar 26.
6
Uphill battle: Innovation of thiopurine therapy in global inflammatory bowel disease care. uphill battle:硫唑嘌呤治疗在全球炎症性肠病治疗中的创新。
Indian J Gastroenterol. 2024 Feb;43(1):36-47. doi: 10.1007/s12664-024-01529-x. Epub 2024 Feb 21.
7
Anti-inflammatory natural products modulate interleukins and their related signaling markers in inflammatory bowel disease: A systematic review.抗炎天然产物对炎症性肠病中白细胞介素及其相关信号标志物的调节作用:一项系统评价。
J Pharm Anal. 2023 Dec;13(12):1408-1428. doi: 10.1016/j.jpha.2023.09.012. Epub 2023 Sep 22.
8
Inflammatory bowel disease (IBD) in rural and urban India: results from community colonoscopic evaluation of more than 30,000 symptomatic patients.印度城乡地区的炎症性肠病(IBD):对30000多名有症状患者进行社区结肠镜评估的结果
Lancet Reg Health Southeast Asia. 2023 Aug 3;19:100259. doi: 10.1016/j.lansea.2023.100259. eCollection 2023 Dec.
9
Challenges in the diagnosis and management of IBD: a sub-Saharan African perspective.炎症性肠病诊断与管理中的挑战:撒哈拉以南非洲地区的视角
Therap Adv Gastroenterol. 2023 Jul 12;16:17562848231184986. doi: 10.1177/17562848231184986. eCollection 2023.
195 个国家和地区 1990-2017 年炎症性肠病的全球、区域和国家负担:2017 年全球疾病负担研究的系统分析。
Lancet Gastroenterol Hepatol. 2020 Jan;5(1):17-30. doi: 10.1016/S2468-1253(19)30333-4. Epub 2019 Oct 21.
4
Rural and urban disparities in the care of Canadian patients with inflammatory bowel disease: a population-based study.加拿大炎症性肠病患者护理中的城乡差异:一项基于人群的研究。
Clin Epidemiol. 2018 Nov 8;10:1613-1626. doi: 10.2147/CLEP.S178056. eCollection 2018.
5
Population Density and Risk of Inflammatory Bowel Disease: A Prospective Population-Based Study in 13 Countries or Regions in Asia-Pacific.人群密度与炎症性肠病风险:亚太地区 13 个国家或地区的前瞻性人群研究
Am J Gastroenterol. 2019 Jan;114(1):107-115. doi: 10.1038/s41395-018-0233-2.
6
Epidemiology of Inflammatory Bowel Disease in India: The Great Shift East.印度炎症性肠病的流行病学:向东方的重大转变。
Inflamm Intest Dis. 2017 Nov;2(2):102-115. doi: 10.1159/000465522. Epub 2017 Apr 8.
7
Efficacy and safety of the adalimumab biosimilar Exemptia as induction therapy in moderate-to-severe ulcerative colitis.阿达木单抗生物类似药Exemptia作为中重度溃疡性结肠炎诱导治疗的疗效与安全性
Intest Res. 2018 Jan;16(1):83-89. doi: 10.5217/ir.2018.16.1.83. Epub 2018 Jan 18.
8
Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies.21 世纪全球炎症性肠病的发病率和流行率:基于人群的系统综述研究。
Lancet. 2017 Dec 23;390(10114):2769-2778. doi: 10.1016/S0140-6736(17)32448-0. Epub 2017 Oct 16.
9
Diet and microbiota in inflammatory bowel disease: The gut in disharmony.炎症性肠病中的饮食与微生物群:失调的肠道
World J Gastroenterol. 2017 Mar 28;23(12):2124-2140. doi: 10.3748/wjg.v23.i12.2124.
10
Infliximab-induced tuberculosis in patients with UC: Experience from India-a country with high prevalence of tuberculosis.英夫利昔单抗诱导的溃疡性结肠炎患者结核病:来自印度(一个结核病高流行国家)的经验。
J Gastroenterol Hepatol. 2017 Jun;32(6):1191-1194. doi: 10.1111/jgh.13669.